{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T23:57:02Z","timestamp":1775347022022,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/s1470-2045(14)70402-4","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T13:33:53Z","timestamp":1410788033000},"page":"1254-1262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data"],"prefix":"10.1016","volume":"15","author":[{"given":"Antonio","family":"Rossi","sequence":"first","affiliation":[]},{"given":"Paolo","family":"Chiodini","sequence":"additional","affiliation":[]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[]},{"given":"Mary E R","family":"O'Brien","sequence":"additional","affiliation":[]},{"given":"Christian","family":"von Plessen","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Barata","sequence":"additional","affiliation":[]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[]},{"given":"Bengt","family":"Bergman","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Parente","sequence":"additional","affiliation":[]},{"given":"Ciro","family":"Gallo","sequence":"additional","affiliation":[]},{"given":"Cesare","family":"Gridelli","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Perrone","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(14)70402-4_bib1","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/S1470-2045(14)70402-4_bib2","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1200\/JCO.2010.34.2774","article-title":"2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guidelines update on chemotherapy for stage IV non-small-cell lung cancer","volume":"29","author":"Azzoli","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/S1470-2045(14)70402-4_bib3","doi-asserted-by":"crossref","first-page":"vii56","DOI":"10.1093\/annonc\/mds226","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Peters","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","article-title":"2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines in advanced disease","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(14)70402-4_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib8","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1200\/JCO.2012.47.3983","article-title":"ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with and without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib9","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","article-title":"Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-small cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial","volume":"25","author":"Barlesi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib11","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.2001.19.5.1336","article-title":"Duration of chemotherapy in advanced nonsmall-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin","volume":"19","author":"Smith","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.bjc.6603383","article-title":"Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer","volume":"95","author":"von Plessen","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(14)70402-4_bib13","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2007.10.8134","article-title":"Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer","volume":"25","author":"Park","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejca.2008.11.006","article-title":"Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis","volume":"45","author":"Lima","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(14)70402-4_bib15","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2008.19.4522","article-title":"Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials","volume":"27","author":"Soon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/S1470-2045(14)70402-4_bib16","doi-asserted-by":"crossref","first-page":"S666","DOI":"10.1097\/01.JTO.0000283943.70775.a5","article-title":"Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine","volume":"2","author":"Barata","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/S1470-2045(14)70402-4_bib18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/sim.2050","article-title":"Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes","volume":"24","author":"Smith","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/S1470-2045(14)70402-4_bib19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/(SICI)1097-0258(19990430)18:8<893::AID-SIM84>3.0.CO;2-5","article-title":"Exact and asymptotic tests for homogeneity in several 2 \u00d7 2 tables","volume":"18","author":"Reis","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/S1470-2045(14)70402-4_bib20","first-page":"1107","article-title":"Cisplatin and vindesine for disseminated non-small cell lung cancer. Results of a prospective trial with 81 patients","volume":"77","author":"Tourani","year":"1990","journal-title":"Bull Cancer"},{"issue":"suppl 1","key":"10.1016\/S1470-2045(14)70402-4_bib21","first-page":"S682","article-title":"Optimal duration of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC) in the 1st and 2nd line settings","volume":"4","author":"Grossi","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/S1470-2045(14)70402-4_bib22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/JTO.0b013e318189f551","article-title":"The prognostic and predictive role of histology in advanced non-small cell lung cancer. A literature review","volume":"3","author":"Hirsch","year":"2008","journal-title":"J Thorac Oncol"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204514704024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204514704024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:10:56Z","timestamp":1761459056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204514704024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1470204514704024"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(14)70402-4","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(14)70402-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(14)70434-6","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}